Metabolic Brain Disease

, Volume 33, Issue 4, pp 1069–1079 | Cite as

Taxifolin prevents β-amyloid-induced impairments of synaptic formation and deficits of memory via the inhibition of cytosolic phospholipase A2/prostaglandin E2 content

  • Yuanyuan Wang
  • Qinwen Wang
  • Xiaoming Bao
  • Yanfei Ding
  • Jieyi Shentu
  • Wei Cui
  • Xiaowei Chen
  • Xiaofei Wei
  • Shujun Xu
Original Article


Taxifolin is a potent flavonoid with anti-inflammatory activity. Taxifolin has been reported to decrease the accumulation of β-amyloid (Aβ), and reduce Aβ-induced neurotoxicity. However, the detail molecular mechanism of taxifolin against Aβ-induced neurotoxicity is largely unknown. In this study, we revealed the protective effects and the underlying mechanisms of taxifolin on the impairments of cognitive function and synapse formation induced by soluble Aβ oligomers. Our results showed that taxifolin prevented neuronal cell death in a concentration-dependent manner. The recognition memory in novel object recognition tasks and the spatial memory in Morris water maze tests are significantly lower in the Alzheimer’s disease (AD) model mice induced by hippocampal injection of Aβ42. Taxifolin treatment prevented the recognitive and spatial memory deficits of the AD mice. 10 mg/kg taxifolin treatment also significantly prevented the decreased expression levels of PSD 95 induced by Aβ42. Live cell imaging study showed that 2 h pre-treatment of taxifolin prevented the decrease in the number of filopodium and spine induced by Aβ42 oligomers. Aβ42 oligomers significantly increased the production of cytosolic phospholipase A2 (cPLA2), a crucial enzyme of pro-inflammatory mediator, and prostaglandin E2 (PGE2), a neuroinflammatory molecule. Taxifolin significantly reduced the content of cPLA2 and PGE2 induced by Aβ42 both in the primary hippocampal neurons and hippocampal tissues. These results indicated that taxifolin might prevent Aβ42 oligomer-induced synapse and cognitive impairments through decreasing cPLA2 and PGE2. Our study provided novel insights into the cellular mechanisms for the protective effects of taxifolin on AD.


Taxifolin Alzheimer’s disease Cognitive impairments Synapse Prostaglandin E2 Cytosolic phospholipase A2 



Alzheimer’s disease

Amyloid-β protein


Prostaglandin E2


Soluble oligomers of Aβ


Cytosolic phospholipase A2


Arachidonic Acid



This work was supported by grants from The National Natural Science Foundation of China (81771166 and 81471398), Natural Science Foundation of Zhejiang Province (LY16H090001 and LY14H090004), Natural Science Foundation of Ningbo (2015A610211), Ningbo municipal innovation team of life science and health (2015C110026), and the K.C.Wong Magna Fund in Ningbo University.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest.


  1. Albert MS (2011) Changes in cognition. Neurobiol Aging 32:58–63CrossRefGoogle Scholar
  2. Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, Hou S, Lattarulo CR, Belcher AM, Shakerdge N, Trujillo PB, Muzikansky A, Betensky RA, Hyman BT, Bacskai BJ (2017) Soluble oligomeric amyloid-beta induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegener 12:27–40CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. J Lancet 377:1019–1031CrossRefGoogle Scholar
  4. Bate C, Williams A (2015a) Alpha-Synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2. Biomol Ther 5:178–193Google Scholar
  5. Bate C, Williams A (2015b) cAMP-inhibits cytoplasmic phospholipase a(2) and protects neurons against amyloid-beta-induced synapse damage. Biol (Basel) 4:591–606Google Scholar
  6. Bate C, Tayebi M, Williams A (2010) Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener 5:13CrossRefPubMedPubMedCentralGoogle Scholar
  7. Brummett AM, Navratil AR, Bryan JD, Woolard MD (2014) Janus kinase 3 activity is necessary for phosphorylation of cytosolic phospholipase A2 and prostaglandin E2 synthesis by macrophages infected with Francisella tularensis live vaccine strain. Infect Immun 82:970–982CrossRefPubMedPubMedCentralGoogle Scholar
  8. Ford L, Crossley M, Williams T, Thorpe JR, Serpell LC, Kemenes G (2015) Effects of Abeta exposure on long-term associative memory and its neuronal mechanisms in a defined neuronal network. Sci Rep 5:10614–10628CrossRefPubMedPubMedCentralGoogle Scholar
  9. Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, Schuler DR, Cirrito JR, Lesne SE, Jankowsky JL (2014) Genetic modulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci 34:7871–7885CrossRefPubMedPubMedCentralGoogle Scholar
  10. Hermann PM, Watson SN, Wildering WC (2014) Phospholipase A2 - nexus of aging, oxidative stress, neuronal excitability, and functional decline of the aging nervous system? Insights from a snail model system of neuronal aging and age-associated memory impairment. Front Genet 5:1–18CrossRefGoogle Scholar
  11. Jiang L, Huang M, Xu S, Wang Y, An P, Feng C, Chen X, Wei X, Han Y, Wang Q (2016) Bis(propyl)-cognitin prevents beta-amyloid-induced memory deficits as well as synaptic formation and plasticity impairments via the activation of PI3-K pathway. Mol Neurobiol 53:3832–3841CrossRefPubMedGoogle Scholar
  12. Koch H, Huh SE, Elsen FP, Carroll MS, Hodge RD, Bedogni F, Turner MS, Hevner RF, Ramirez JM (2010) Prostaglandin E2-induced synaptic plasticity in neocortical networks of organotypic slice cultures. J Neurosci 30:11678–11687CrossRefPubMedPubMedCentralGoogle Scholar
  13. Koffie RM, Hyman BT, Spires-Jones TL (2011) Alzheimer's disease: synapses gone cold. Mol Neurodegener 6:63–71CrossRefPubMedPubMedCentralGoogle Scholar
  14. Larson ME, Lesne SE (2012) Soluble Abeta oligomer production and toxicity. J Neurochem 120:125–139CrossRefPubMedGoogle Scholar
  15. Marjani M, Baghaei P, Fahimic F, Dizajib MK, Tabarsi P, Bayani PG, Velayati AA (2016) Evaluation of Hepatoprotective effect of Silymarin among under treatment tuberculosis patients: a randomized clinical trial. Iran J Pharm Res 15:247–252PubMedPubMedCentralGoogle Scholar
  16. Naito Y, Tanabe Y, Lee AK, Hamel E, Takahashi H (2017) Amyloid-beta oligomers interact with Neurexin and diminish Neurexin-mediated excitatory presynaptic organization. Sci Rep 7:42548–42560CrossRefPubMedPubMedCentralGoogle Scholar
  17. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381CrossRefPubMedPubMedCentralGoogle Scholar
  18. Ni J, Wu Z, Meng J, Zhu A, Zhong X, Wu S, Nakanishi H (2017) The neuroprotective effects of Brazilian green Propolis on neurodegenerative damage in human neuronal SH-SY5Y cells. Oxid Med Cell Longev 2017:1–13CrossRefGoogle Scholar
  19. Park SY, Kim HY, Park HJ, Shin HK, Hong KW, Kim CD (2016) Concurrent treatment with Taxifolin and Cilostazol on the lowering of beta-amyloid accumulation and neurotoxicity via the suppression of P-JAK2/P-STAT3/NF-kappaB/BACE1 signaling pathways. PLoS One 11:e0168286CrossRefPubMedPubMedCentralGoogle Scholar
  20. Price KA, Varghese M, Sowa A, Yuk F, Brautigam H, Dickstein DL (2014) Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-β oligomers and no plaque pathology. Mol Neurodegener 9:41–53CrossRefPubMedPubMedCentralGoogle Scholar
  21. Saito S, Yamamoto Y, Maki T, Hattori Y, Ito H, Mizuno K, Harada-Shiba M, Kalaria RN, Fukushima M, Takahashi R, Ihara M (2017) Taxifolin inhibits amyloid-beta oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy. Acta Neuropathol Commun 5:26CrossRefPubMedPubMedCentralGoogle Scholar
  22. Sato M, Murakami K, Uno M, Ikubo H, Nakagawa Y, Katayama S, Akagi K, Irie K (2013a) Structure-activity relationship for (+)-taxifolin isolated from silymarin as an inhibitor of amyloid beta aggregation. Biosci Biotechnol Biochem 77:1100–1103CrossRefPubMedGoogle Scholar
  23. Sato M, Murakami K, Uno M, Nakagawa Y, Katayama S, Akagi K, Masuda Y, Takegoshi K, Irie K (2013b) Site-specific inhibitory mechanism for amyloid beta42 aggregation by catechol-type flavonoids targeting the Lys residues. J Biol Chem 288:23212–23224CrossRefPubMedPubMedCentralGoogle Scholar
  24. Schwab C, McGeer PL (2008) Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 13:359–369CrossRefPubMedGoogle Scholar
  25. Sun GY, Chuang DY, Zong Y, Jiang J, Lee JC, Gu Z, Simonyi A (2014) Role of cytosolic phospholipase A2 in oxidative and inflammatory signaling pathways in different cell types in the central nervous system. Mol Neurobiol 50:6–14CrossRefPubMedPubMedCentralGoogle Scholar
  26. Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L (2014) Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 41:615–631CrossRefPubMedGoogle Scholar
  27. Teich AF, Nicholls RE, Puzzo D, Fiorito J, Purgatorio R, Fa M, Arancio O (2015) Synaptic therapy in Alzheimer's disease: a CREB-centric approach. Neurotherapeutics 12:29–41CrossRefPubMedPubMedCentralGoogle Scholar
  28. Topal F, Nar M, Gocer H, Kalin P, Kocyigit UM, Gulcin I, Alwasel SH (2016) Antioxidant activity of taxifolin: an activity-structure relationship. J Enzyme Inhib Med Chem 31:674–683CrossRefPubMedGoogle Scholar
  29. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370–3378CrossRefPubMedGoogle Scholar
  30. Wang Q, Wang L, Li G, Ye B (2017) A simple and sensitive method for determination of taxifolin on palladium nanoparticles supported poly (diallyldimethylammonium chloride) functionalized graphene modified electrode. Talanta 164:323–329CrossRefPubMedGoogle Scholar
  31. Wang-Dietrich L, Funke SA, Kuhbach K, Wang K, Besmehn A, Willbold S, Cinar Y, Bannach O, Birkmann E, Willbold D (2013) The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J Alzheimers Dis 34:985–994CrossRefPubMedGoogle Scholar
  32. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2:a006346–a006368CrossRefPubMedPubMedCentralGoogle Scholar
  33. Xu S, Guan Q, Wang C, Wei X, Chen X, Zheng B, An P, Zhang J, Chang L, Zhou W, Mody I, Wang Q (2014a) Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses. Neurosci Lett 578:7–11CrossRefPubMedGoogle Scholar
  34. Xu S, Liu G, Bao X, Wu J, Li S, Zheng B, Anwyl R, Wang Q (2014b) Rosiglitazone prevents amyloid-beta oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. J Alzheimers Dis 39:239–251CrossRefPubMedGoogle Scholar
  35. Yang P, Xu F, Li HF, Wang Y, Li FC, Shang MY, Liu GX, Wang X, Cai SQ (2016) Detection of 191 Taxifolin metabolites and their distribution in rats using HPLC-ESI-IT-TOF-MS(n). Molecules 21:1209–1234Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Zhejiang Provincial Key Laboratory of PathophysiologySchool of Medicine Ningbo UniversityZhejiangChina
  2. 2.The No.2 Hospital of NingboZhejiangChina

Personalised recommendations